La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alaunos Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alaunos Therapeutics..

Alaunos Therapeutics (NASDAQ:TCRT) Azioni, Catena delle Opzioni

Alaunos Therapeutics

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.

Goldman Sachs analyst James Schneider initiates coverage on Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral rating and announces Price Target of $85.

News

Price Target

Initiation

Analyst Ratings

ENTG

Goldman Sachs Initiates Coverage On Entegris with Neutral Rating, Announces Price Target of $85

As JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) prepares to unveil its second-quarter earnings on July 15, the financial world is bracing for a significant shift that reflects broader economic trends. Over the past year, rising interest rates and inflationary pressures have squeezed borrowers and heightened market volatility, factors that are expected to dampen <a href="https://www.benzinga.com/quote/JPM/earnings">the bank&#8217;s profits.</a>
Analysts expect the company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Wednesday, Truist Securities analyst John McDonald maintained a Hold rating on JPMorgan and raised the price target from $280 to $290.
With the recent buzz around JPMorgan, some investors may be eyeing potential gains from the company's dividends. As of now, JPMorgan offers an annual dividend yield of 1.98%, which is a quarterly dividend amount of $1.40 per share ($5.60 a year).
To figure out how to earn $500 monthly from JPMorgan, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by JPMorgan's $5.60 dividend: $6,000 / $5.60 = 1,071 shares.
So, an investor would need to own approximately $303,264 worth of JPMorgan, or 1,071 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $5.60 = 214 shares, or $60,596 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
JPM Price Action: Shares of JPMorgan gained by 0.1% to close at $283.16 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo: Rokas Tenys/Shutterstock

Earnings

Long Ideas

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy and maintains $14 price target.

NRSN

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

WIIM

SAFX

XCF Global shares are trading higher after the company announced it will invest $1 billion in U.S. SAF plants.

Goldman Sachs analyst James Schneider initiates coverage on KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Neutral rating and announces Price Target of $980.

KLAC

Goldman Sachs Initiates Coverage On KLA with Neutral Rating, Announces Price Target of $980

DALN

DallasNews shares are trading higher after the company announced Hearst will acquire it for $14 per share.

KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.82) by 20.58 percent. This is a 2.94 percent increase over losses of $(1.02) per share from the same period last year.

Earnings Misses

KALV

KalVista Pharma Q4 EPS $(0.99) Misses $(0.82) Estimate

&nbsp;K Wave Media Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kwm#NASDAQ">KWM</a>) ("K Wave" or the "Company"), the first Nasdaq-listed public company to integrate Korean cultural content with a Bitcoin-focused corporate treasury model, today announced entering into
&nbsp;K Wave Media Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) ("K Wave" or the "Company"), the first Nasdaq-listed public company to integrate Korean cultural content with a Bitcoin-focused corporate treasury model, today announced entering into a convertible note agreement with Anson Funds where Anson agreed to provide up to $500 million in financing under which KWM will allocate minimum 80% of the net proceeds toward purchase of BTC. The first tranche will be the issuance and sale of $15 million in senior secured convertible notes and warrants to Anson Investments Master Fund, LP, and Anson East Master Fund LP pursuant to a securities purchase agreement.
This follows the previously announced $500 million Standby Equity Purchase Agreement (SEPA) with Bitcoin Strategic Reserve, bringing the Company's total capital capacity for its treasury initiative to $1 billion.
With execution underway, KWM has completed its initial acquisition of "88" BTC. "88", widely regarded as a symbol of fortune and success in Asian culture, demonstrates firm conviction in Bitcoin as a superior long-term investment. The Company intends to scale its holdings of Bitcoin aggressively and transparently, aligning itself with the monetary principles of Bitcoin and the growing global movement of on-chain corporate reserves.
"We believe that this financing structure positions us to execute one of the most ambitious corporate Bitcoin accumulation strategies in the world," said Ted Kim, CEO of K Wave Media. "Our objective is clear: to scale our holdings toward 10,000 Bitcoin as soon as possible while maintaining strong investor alignment and full transparency in treasury reporting. At the same time, our existing K-content businesses stand to benefit from this BTC-driven treasury strategy as we actively explore innovative ways for global fans to engage with, consume, and even invest in our premium movies and dramas using Bitcoin."
Amin Nathoo, CEO of Anson, said, "We are excited to partner with K Wave and their impressive management team as they execute on both the K-content and Bitcoin treasury opportunities."
KWM's model combines capital markets sophistication with cultural resonance. By anchoring Bitcoin to a forward-looking media platform, the Company aims to create new pathways for investor participation and global engagement and be a leader in the Web3 economy.

Small Cap

Treasuries

K Wave Media Announces It Has Secured $1B Capital Capacity To Drive Bitcoin Treasury Strategy As Well As A $500M Convertible Note With Anson Funds

Cantor Fitzgerald analyst Brett Knoblauch maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Overweight and raises the price target from $21 to $23.

BTDR

Cantor Fitzgerald Maintains Overweight on Bitdeer Technologies, Raises Price Target to $23

Goldman Sachs analyst James Schneider initiates coverage on MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Sell rating and announces Price Target of $90.

MKSI

Goldman Sachs Initiates Coverage On MKS with Sell Rating, Announces Price Target of $90

Methode Electronics shares are trading lower after the company reported a Q4 adjusted EPS miss and issued FY26 revenue guidance below estimates.

Goldman Sachs analyst James Schneider initiates coverage on Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Sell rating and announces Price Target of $80.

Goldman Sachs Initiates Coverage On Teradyne with Sell Rating, Announces Price Target of $80

HELE

Helen of Troy shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates.

Goldman Sachs analyst James Schneider initiates coverage on SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Buy rating and announces Price Target of $55.

SNDK

Goldman Sachs Initiates Coverage On SanDisk with Buy Rating, Announces Price Target of $55

MREO

Mereo BioPharma Group shares are trading lower after Needham cut its price target on the stock from $7 to $5.

Goldman Sachs analyst Toshiya Hari initiates coverage on Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy rating and announces Price Target of $170.

Goldman Sachs Initiates Coverage On Seagate Tech Hldgs with Buy Rating, Announces Price Target of $170

ConAgra Brands shares are trading lower after the company reported worse-than-expected Q4 financial results and issued FY26 adjusted EPS guidance below estimates.

Goldman Sachs analyst Toshiya Hari initiates coverage on Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy rating and announces Price Target of $115.

LRCX

Goldman Sachs Initiates Coverage On Lam Research with Buy Rating, Announces Price Target of $115

SMPL

Simply Good Foods shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 sales guidance below estimates.

Goldman Sachs analyst Christine Cho downgrades Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) from Buy to Neutral and raises the price target from $66 to $67.

Downgrades

CAKE

Goldman Sachs Downgrades Cheesecake Factory to Neutral, Raises Price Target to $67

Press Releases

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

ELAB

TCRT

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Aprea Therapeutics

Aptevo Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CEL-SCI

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Genprex

HCW Biologics

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Moleculin Biotech

Mainz Biomed

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

TAO Synergies

Alaunos Therapeutics, Inc. - Common Stock

Comments

Alaunos Therapeutics

Alaunos Therapeutics (TCRT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO